Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-Vessel Vasculitis (Takayasu's Arteritis): Development as clinical trial outcome measures - VCRC 5515

ABSTRACT: VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-Vessel Vasculitis (Takayasu's Arteritis): Development as clinical trial outcome measures - VCRC 5515

PROVIDER: PRJNA497166 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-Vessel Vasculitis (Takayasu's Arteritis): Development as clinical trial outcome measures - VCRC 5515

Project description:VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-Vessel Vasculitis (Takayasu's Arteritis): Development as clinical trial outcome measures - VCRC 5515

| PRJNA497165 | ENA

VCRC Longitudinal Protocol for Takayasu's Arteritis - VCRC 5503

Project description:VCRC Longitudinal Protocol for Takayasu's Arteritis - VCRC 5503

| PRJNA188259 | ENA

VCRC Longitudinal Protocol for Polyarteritis Nodosa - VCRC 5504

Project description:VCRC Longitudinal Protocol for Polyarteritis Nodosa - VCRC 5504

| PRJNA188261 | ENA

Homo sapiens

Project description:VCRC Longitudinal Protocol for Takayasu's Arteritis - VCRC 5503

| PRJNA188260 | ENA

Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis.

Project description:OBJECTIVES:To assess agreement between interpretation of magnetic resonance angiography (MRA) and 18F-fluorodeoxyglucose positron emission tomography (PET) for disease extent and disease activity in large-vessel vasculitis (LVV) and determine associations between imaging and clinical assessments. METHODS:Patients with giant cell arteritis (GCA), Takayasu's arteritis (TAK) and comparators were recruited into a prospective, observational cohort. Imaging and clinical assessments were performed concurrently, blinded to each other. Agreement was assessed by per cent agreement, Cohen's kappa and McNemar's test. Multivariable logistic regression identified MRA features associated with PET scan activity. RESULTS:Eighty-four patients (GCA=35; TAK=30; comparator=19) contributed 133 paired studies. Agreement for disease extent between MRA and PET was 580 out of 966 (60%) arterial territories with Cohen's kappa=0.22. Of 386 territories with disagreement, MRA demonstrated disease in more territories than PET (304vs82, p<0.01). Agreement for disease activity between MRA and PET was 90 studies (68%) with Cohen's kappa=0.30. In studies with disagreement, MRA demonstrated activity in 23 studies and PET in 20 studies (p=0.76). Oedema and wall thickness on MRA were independently associated with PET scan activity. Clinical status was associated with disease activity by PET (p<0.01) but not MRA (p=0.70), yet 35/69 (51%) patients with LVV in clinical remission had active disease by both MRA and PET. CONCLUSIONS:In assessment of LVV, MRA and PET contribute unique and complementary information. MRA better captures disease extent, and PET scan is better suited to assess vascular activity. Clinical and imaging-based assessments often do not correlate over the disease course in LVV. TRIAL REGISTRATION NUMBER:NCT02257866.

| S-EPMC6045453 | biostudies-literature

VCRC Longitudinal Protocol for Churg-Strauss Syndrome - VCRC 5506

Project description:VCRC Longitudinal Protocol for Churg-Strauss Syndrome - VCRC 5506

| PRJNA188338 | ENA

VCRC Longitudinal Protocol for Giant Cell Arteritis - VCRC 5502

Project description:VCRC Longitudinal Protocol for Giant Cell Arteritis - VCRC 5502

| PRJNA198757 | ENA

VCRC Genetic Repository One-Time DNA Protocol - VCRC 5510

Project description:VCRC Genetic Repository One-Time DNA Protocol - VCRC 5510

| PRJNA496249 | ENA

VCRC Genetic Repository One-Time DNA Protocol - VCRC 5510

Project description:VCRC Genetic Repository One-Time DNA Protocol - VCRC 5510

| PRJNA496250 | ENA

18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.

Project description:Fluorine-18-fluoro-2-deoxy-D-glucose (FDG) is widely used as positron-emission-tomography (PET) radiotracer for the detection and staging of human cancer. Tumor uptake of FDG varies substantially between different cancer types and between patients with the same tumor type. The molecular basis for this heterogeneity is unknown. Using cancer cell lines and primary human tumors of distinct histologic origins, we here show that increased FDG uptake is universally associated with coordinate upregulation of genes within the glycolysis, pentose-phosphate, and other related metabolic pathways. In primary human breast cancers, this FDG signature shows significant overlap with established breast cancer signatures for the “basal-like” disease subtype and “poor prognosis”. FDG high breast cancer showed significantly more gene copy number alterations genome wide than FDG low cancers. About 50 % of primary breast cancers with high FDG uptake and FDG gene expression signature show DNA copy gain encompassing the c-myc gene locus and express gene sets regulated by the transcription factor MYC. Our data shows that FDG-PET marks a distinct subset of “basal-like” human breast cancer which is characterized by MYC and prognostically unfavorable gene expression signatures, suggesting that FDG-PET imaging may be useful to risk-stratify patients with locally advanced breast cancer.

2011-11-01 | GSE21217 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data